L'AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) GRANDE OSPEDALE METROPOLITANO NIGUARDA

Their core work

ASST Grande Ospedale Metropolitano Niguarda is one of Milan's largest public hospitals, serving as a clinical research site that bridges neuroscience and metabolic disease. In H2020, they contributed clinical expertise and patient data to the Human Brain Project — Europe's flagship brain research initiative — across three successive grant agreements plus the supporting computing infrastructure. They also participated in clinical trials for advanced diabetes therapies (DRIVE, DELIVER) and molecularly guided oncology treatment (MoTriColor), reflecting their role as a frontline hospital that feeds real-world clinical evidence into large-scale European research programs.

What they specialise in

How they've shifted over time

In the early period (2015-2018), Niguarda's involvement centered on foundational neuroscience — mouse and human brain reconstruction, transcriptome analysis, and biological signatures of disease — alongside initial diabetes implant research. By 2018-2023, their focus shifted toward computational neuroscience infrastructure: federated data systems, interactive supercomputing, brain modeling on the EBRAINS platform, and connectomics. This evolution mirrors the Human Brain Project's own trajectory from basic neuroscience toward building a permanent European research infrastructure.

Moving from contributing clinical neuroscience data toward supporting federated brain research infrastructure, suggesting future interest in digital health platforms and neuroinformatics services.

How they like to work

Niguarda operates exclusively as a participant or third party — never as a coordinator — which is typical of a large clinical institution contributing domain expertise rather than managing research programs. Their 180 unique partners across 21 countries is impressive but largely driven by the massive Human Brain Project consortia (100+ partners per SGA). This means they are experienced working within very large, complex European collaborations and comfortable with distributed governance structures.

Connected to 180 unique partners across 21 countries, though this extensive network is primarily a byproduct of the Human Brain Project's mega-consortia rather than independently built relationships. Their core collaborative ties are with major European neuroscience centers and university hospitals.

What sets them apart

Niguarda's distinctiveness lies in being a large metropolitan hospital — not a university or research institute — embedded in Europe's most ambitious neuroscience program. This gives them a rare combination: direct access to clinical patient populations (neurological, diabetic, oncological) alongside deep experience in large-scale brain research infrastructure. For consortium builders, they offer something universities cannot — a working hospital environment where research outputs can be validated against real clinical workflows.

Highlights from their portfolio

• HBP SGA3
  The culminating phase of the Human Brain Project, building the permanent EBRAINS infrastructure — positions Niguarda within Europe's most high-profile neuroscience initiative.
• MoTriColor
  Their largest funded project (EUR 207,501), a precision oncology trial for colorectal cancer using molecular stratification — shows clinical trial capability beyond neuroscience.
• DELIVER
  An MSCA training network for advanced diabetes therapies, where Niguarda joined as a third party — indicating their value as a clinical training site for early-career researchers.